Recent Company News

• 09:43 AM ET Jul 29, 2025
  

  BioMedNewsBreaks -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier

• 07:15 AM ET Jul 29, 2025
  

  Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

• 07:10 AM ET Jul 23, 2024
  

  Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)

• 02:02 PM ET Mar 15, 2024
  

  StreetAccount Activist Summary: Week of 11-Mar

• 04:21 PM ET Mar 12, 2024
  

  Scinai Immunotherapeutics 12.96% shareholder Daniel Stone files 13D - 13D ($0.52, 0.00)

• 06:20 AM ET Jan 04, 2024
  

  Scinai Immunotherapeutics provides update on 2024 plans ($0.59, 0.00)

• 09:28 AM ET Dec 29, 2023
  

  Scinai Immunotherapeutics announces exercise of outstanding warrants for $1.69M in gross proceeds ($0.70, 0.00)

• 07:32 AM ET Dec 12, 2023
  

  Scinai reports results from preclinical study of NanoAb in psoriatic human skin model ($0.70, 0.00)

• 08:14 AM ET Dec 11, 2023
  

  Scinai Immunotherapeutics announces publication of study supporting coronavirus NanoAb as aerosolized prophylactic and therapeutic drug ($0.70, 0.00)

• 07:34 AM ET Nov 06, 2023
  

  Scinai Immunotherapeutics award of non-dilutive grant from Israel Innovation Authority supporting its new CDMO business unit ($0.67, 0.00)